Systemic lupus erythematosus (SLE) is associated with considerable cardiovascular morbidity that has not yet been directly compared with other diseases with known cardiovascular risk.
Methods
Two hundred and forty-one patients of the multicentre Swiss SLE cohort study (SSCS) were cross-sectionally assessed for coronary heart disease (CHD), cerebrovascular disease (CVD) and peripheral artery disease (PAD). SLE patients were compared with a cohort of 193 patients with type-1 diabetes mellitus being followed at the University Hospital Basel. A subgroup analysis of 50 age- and sex-matched patients from the University Hospital Basel was performed.
Results
Of patients within the SSCS 13.3% had one or more vascular events: 8.3% CHD, 5% CVD and 1.2% PAD. In type-1 diabetes mellitus patients, 15% had vascular events: 9.3% CHD, 3.1% CVD and 5.6% PAD. In the matched subgroup, 26% of SLE patients had vascular events (14% CHD) compared with 12% in type-1 DM patients (2% CHD). Cardiovascular risk factors were similar in both groups. Vascular events in SLE patients were associated with age, longer disease duration, dyslipidaemia, and hypertension.
Conclusion
Cardiovascular morbidity in SLE is at least as frequent as in age- and sex-matched type-1 diabetes mellitus patients. Therefore, aggressive screening and management of cardiovascular risk factors should be performed.
JacobsenSPetersenJUllmanS. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol1998; 17: 478–484.
2.
UrowitzMBBookmanAAKoehlerBE. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med1976; 60: 221–225.
3.
SchoenfeldSRKasturiSCostenbaderKH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. Semin Arthritis Rheum2013; 43: 77–95.
4.
BjornadalLYinLGranathF. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: Results from a Swedish population based study 1964-95. J Rheumatol2004; 31: 713–719.
5.
BernatskySBoivinJFJosephL. Mortality in systemic lupus erythematosus. Arthritis Rheum2006; 54: 2550–2557.
6.
DoriaAIaccarinoLGhirardelloA. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med2006; 119: 700–706.
7.
GustafssonJTSimardJFGunnarssonI. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther2012; 14: R46–R46.
8.
ManziSMeilahnENRairieJE. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol1997; 145: 408–415.
9.
WardMM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum1999; 42: 338–346.
10.
EsdaileJMAbrahamowiczMGrodzickyT. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum2001; 44: 2331–2337.
11.
MagderLSPetriM. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol2012; 176: 708–719.
12.
LeonardDSvenungssonESandlingJK. Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. Circ Cardiovasc Genet2013; 6: 255–263.
13.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
14.
AlbrechtDPuderJKellerU. Potential of education-based insulin therapy for achievement of good metabolic control: A real-life experience. Diabet Med2011; 28: 539–542.
15.
ChobanianAVBakrisGLBlackHR. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension2003; 42: 1206–1252.
16.
UrowitzMBGladmanDIbanezD. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken)2010; 62: 881–887.
17.
Pons-EstelGJGonzalezLAZhangJ. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: Data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford)2009; 48: 817–822.
18.
BorchersATKeenCLShoenfeldY. Surviving the butterfly and the wolf: Mortality trends in systemic lupus erythematosus. Autoimmun Rev2004; 3: 423–453.
PetriMPerez-GutthannSSpenceD. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med1992; 93: 513–519.
21.
SinicatoNAda Silva CardosoPAAppenzellerS. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev2013; 9: 15–19.
22.
SchoenfeldSRKasturiSCostenbaderKH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. Semin Arthritis Rheum2013; 43: 77–95.
23.
ChiuCCHuangCCChanWL. Increased risk of ischemic stroke in patients with systemic lupus erythematosus: A nationwide population-based study. Intern Med2012; 51: 17–21.
24.
HakAEKarlsonEWFeskanichD. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study. Arthritis Rheum2009; 61: 1396–1402.
25.
Soedamah-MuthuSSFullerJHMulnierHE. High risk of cardiovascular disease in patients with type 1 diabetes in the UK: A cohort study using the general practice research database. Diabetes Care2006; 29: 798–804.
26.
BurgosPIVilaLMReveilleJD. Peripheral vascular damage in systemic lupus erythematosus: Data from LUMINA, a large multi-ethnic US cohort (LXIX). Lupus2009; 18: 1303–1308.
27.
ElhaddTAJungRTNewtonRW. Incidence of asymptomatic peripheral arterial occlusive disease in diabetic patients attending a hospital clinic. Adv Exp Med Biol1997; 428: 45–48.
28.
HirschATCriquiMHTreat-JacobsonD. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA2001; 286: 1317–1324.
29.
MehtaJLSaldeenTGRandK. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol1998; 31: 1217–1225.
PuriRNissenSELibbyP. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation2013; 128: 2395–2403.
32.
PetriMAKianiANPostW. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis2011; 70: 760–765.
33.
SelzerFSutton-TyrrellKFitzgeraldSG. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum2004; 50: 151–159.
34.
BruceINUrowitzMBGladmanDD. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum2003; 48: 3159–3167.
35.
DoriaAShoenfeldYWuR. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis2003; 62: 1071–1077.
36.
BulkleyBHRobertsWC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med1975; 58: 243–264.
37.
SerikovaSIKozlovskaiaNLShilovEM. [Lupus nephritis as a factor of atherosclerosis risk in patients with systemic lupus erythematosus]. Ter Arkh2008; 80: 52–58.
38.
SvenungssonEJensen-UrstadKHeimburgerM. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation2001; 104: 1887–1893.
39.
TolozaSMUribeAGMcGwinGJr. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum2004; 50: 3947–3957.
40.
RomanMJShankerBADavisA. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med2003; 349: 2399–2406.
41.
MannucciEDicembriniILauriaA. Is glucose control important for prevention of cardiovascular disease in diabetes?Diabetes Care2013; 36(Suppl. 2): S259–S263.
42.
NathanDMClearyPABacklundJY. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med2005; 353: 2643–2653.
